Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis Ashwin Kishtagari, MD Vanderbilt-Ingram Cancer Center #mpnsm #oncology onclive.com/view/navigatin…

Older Adults With Aggressive Blood Cancer Are Responsive to Treatment and Show Prolonged Survival Sylvester Comprehensive Cancer Center #leusm #oncology onclive.com/view/older-adu…

Epacadostat Plus Preoperative Chemoradiation Is Feasible in Locally Advanced Rectal Cancer Dana-Farber @aacr #AACR24 #oncology
onclive.com/view/epacadost…

Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2–Breast Cancer
U.S. FDA #bcsm #MedTwitter #oncology
onclive.com/view/inavolisi…

.@us_fda Grants Orphan Drug Designation to Azeliragon for Pancreatic Cancer #pancsm
onclive.com/view/fda-grant…

.U.S. FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors #MedTwitter #oncology #kcsm onclive.com/view/fda-updat…

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors MD Anderson Cancer Center #MedTwitter #oncology onclive.com/view/first-in-…

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer. ESMO - Eur. Oncology Rebecca Dent #oncology #MedTwitter #bcsm #ESMOBreast24 onclive.com/view/atezolizu…

Second- or third-line olaparib, durvalumab, and fulvestrant demonstrated activity and safety in select patients with primarily pretreated, endocrine-resistant ER-positive/HER2-negative metastatic breast cancer. ESMO - Eur. Oncology #ESMOBreast24 #bcsm onclive.com/view/olaparib-…

Pertuzumab plus trastuzumab produced antitumor activity and a mild adverse effect profile in patients with pretreated biliary tract cancer with ERBB2/3 alterations. Inova Journal of Clinical Oncology #MedTwitter #oncology onclive.com/view/pertuzuma…

The FDA has granted accelerated approval to liso-cel for the treatment of adult patients with R/R follicular lymphoma who have received 2 or more prior lines of systemic therapy. U.S. FDA #lymsm onclive.com/view/fda-grant…

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer. ESMO - Eur. Oncology Barts Cancer Institute (Queen Mary) #ESMOBreast24 #bcsm onclive.com/view/frontline…

Samilia Obeng-Gyasi, MD, MPH, discusses research on the association between neighborhood opportunity, allostatic load, and all-cause mortality in patients with stage I to III breast cancer treated at OSUCC. Samilia Obeng-Gyasi, MD, MPH The James #bcsm #oncology onclive.com/view/lower-nei…

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma. Journal of Clinical Oncology Eileen M O’Reilly #oncology #MedTwitter onclive.com/view/capecitab…

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC. Vikram M. Narayan, MD Emory Urologic Oncology #blcsm onclive.com/view/nadofarag…

Efforts to deliver individualized care for patients with advanced urothelial cancer continue to explore novel immunotherapy combinations, resulting in more options in the frontline setting. Petros Grivas Fred Hutchinson Cancer Center #oncology onclive.com/view/grivas-sp…

In this episode of #OncLiveOnAir , Drs Nassar and Bou Farhat, Yale Cancer Center, explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types. #oncology onclive.com/view/bou-farha…

Mike Lattanzi, MD, Texas Oncology, discusses key findings from, and implications of, the phase 3 PROpel trial in patients with metastatic castration-resistant prostate cancer. onclive.com/view/dr-lattan…